BIODESIX INC (BDSX)
US09075X1081 - Common Stock
Overall BDSX gets a fundamental rating of 3 out of 10. We evaluated BDSX against 113 industry peers in the Health Care Providers & Services industry. BDSX has a bad profitability rating. Also its financial health evaluation is rather negative. BDSX is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
BDSX had negative earnings in the past year.
In the past year BDSX has reported a negative cash flow from operations.
BDSX had negative earnings in each of the past 5 years.
In the past 5 years BDSX always reported negative operating cash flow.
1.2 Ratios
With a Return On Assets value of -38.42%, BDSX is not doing good in the industry: 84.07% of the companies in the same industry are doing better.
BDSX has a Return On Equity of -122.76%. This is in the lower half of the industry: BDSX underperforms 76.99% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -38.42% | ||
| ROE | -122.76% | ||
| ROIC | N/A |
ROA(3y)-59.93%
ROA(5y)-55.91%
ROE(3y)-558.46%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
BDSX's Gross Margin of 77.58% is amongst the best of the industry. BDSX outperforms 92.92% of its industry peers.
In the last couple of years the Gross Margin of BDSX has remained more or less at the same level.
BDSX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 77.58% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y12.43%
GM growth 5Y-1.3%
2. Health
2.1 Basic Checks
BDSX does not have a ROIC to compare to the WACC, probably because it is not profitable.
BDSX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for BDSX has been increased compared to 5 years ago.
BDSX has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -3.94, we must say that BDSX is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of BDSX (-3.94) is worse than 85.84% of its industry peers.
BDSX has a Debt/Equity ratio of 0.99. This is a neutral value indicating BDSX is somewhat dependend on debt financing.
BDSX has a worse Debt to Equity ratio (0.99) than 67.26% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.99 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.94 |
ROIC/WACCN/A
WACC9.2%
2.3 Liquidity
BDSX has a Current Ratio of 3.28. This indicates that BDSX is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 3.28, BDSX belongs to the best of the industry, outperforming 89.38% of the companies in the same industry.
A Quick Ratio of 3.28 indicates that BDSX has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 3.28, BDSX belongs to the top of the industry, outperforming 91.15% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.28 | ||
| Quick Ratio | 3.28 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 56.67% over the past year.
The Revenue has grown by 28.47% in the past year. This is a very strong growth!
The Revenue has been growing by 19.16% on average over the past years. This is quite good.
EPS 1Y (TTM)56.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
Revenue 1Y (TTM)28.47%
Revenue growth 3Y2.52%
Revenue growth 5Y19.16%
Sales Q2Q%34.53%
3.2 Future
Based on estimates for the next years, BDSX will show a very strong growth in Earnings Per Share. The EPS will grow by 21.44% on average per year.
BDSX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 31.49% yearly.
EPS Next Y45.08%
EPS Next 2Y28.84%
EPS Next 3Y21.44%
EPS Next 5YN/A
Revenue Next Year42.1%
Revenue Next 2Y35.74%
Revenue Next 3Y31.49%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for BDSX. In the last year negative earnings were reported.
Also next year BDSX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as BDSX's earnings are expected to grow with 21.44% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.84%
EPS Next 3Y21.44%
5. Dividend
5.1 Amount
BDSX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIODESIX INC
NASDAQ:BDSX (11/4/2024, 8:00:00 PM)
1.39
+0.09 (+6.92%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap202.20M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -38.42% | ||
| ROE | -122.76% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 77.58% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.53
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.99 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.28 | ||
| Quick Ratio | 3.28 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)56.67%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y45.08%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)28.47%
Revenue growth 3Y2.52%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y